Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Common Equity: 2022-2024

Historic Common Equity for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $32.6 million.

  • Corvus Pharmaceuticals' Common Equity rose 478.35% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.8 million, marking a year-over-year increase of 478.35%. This contributed to the annual value of $32.6 million for FY2024, which is 15.81% down from last year.
  • Per Corvus Pharmaceuticals' latest filing, its Common Equity stood at $32.6 million for FY2024, which was down 15.81% from $38.7 million recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Common Equity peaked at $56.1 million during FY2022, and registered a low of $32.6 million during FY2024.
  • Its 3-year average for Common Equity is $42.5 million, with a median of $38.7 million in 2023.
  • Data for Corvus Pharmaceuticals' Common Equity shows a maximum YoY crashed of 31.06% (in 2023) over the last 5 years.
  • Over the past 3 years, Corvus Pharmaceuticals' Common Equity (Yearly) stood at $56.1 million in 2022, then plummeted by 31.06% to $38.7 million in 2023, then decreased by 15.81% to $32.6 million in 2024.